Results 111 to 120 of about 43,880 (267)

Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy [PDF]

open access: yes, 2015
The CXC chemokine receptor (CXCR) 3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune disesases. Under the influence of interferon (IFN) γ, the IFNγ-inducible chemokines are secreted by lymphocytes, and by ...
Antonelli, Alessandro   +4 more
core   +1 more source

The mitochondrial‐targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial‐apoptotic but not necroptotic signalling during ovarian cancer

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend An evaluation of the degree to which mitochondrial hydrogen peroxide emission (mH2O2)‐mediated apoptotic and necroptotic signalling contributes to skeletal muscle atrophy in an orthotopic epithelial ovarian cancer (EOC) model. To determine whether attenuating mH2O2 could prevent regulated cell death signalling and mitigate muscle
Shahrzad Khajehzadehshoushtar   +15 more
wiley   +1 more source

Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis [PDF]

open access: yes, 2012
Inclusion body myositis (IBM) belongs to a group of muscle diseases known as the inflammatory myopathies. The presence of antibody-secreting plasma cells in IBM muscle implicates the humoral immune response in this disease.
Amato, Anthony A.   +12 more
core   +4 more sources

Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies [PDF]

open access: bronze, 2021
Sangmee Bae   +10 more
openalex   +1 more source

Tacrolimus Trough Concentration‐Escalating Bipartite Therapy (Glucocorticoids Combined With Tacrolimus) for Refractory MDA5 Antibody‐Positive Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Pneumonia

open access: yesImmunity, Inflammation and Disease, Volume 13, Issue 11, November 2025.
ABSTRACT Objective This study aimed to determine the outcomes of patients that have refractory anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody‐positive clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia treated with tacrolimus trough concentration‐escalating bipartite therapy (glucocorticoids combined ...
Anji Xiong   +10 more
wiley   +1 more source

Why do patients with myositis die? A retrospective analysis of a single-centre cohort [PDF]

open access: yes, 2016
OBJECTIVES: Causes of death in inflammatory myopathies have rarely been studied. We have assessed a cohort of myositis patients followed in a single centre over a 37-year period, reviewing the mortality rate, causes of death and predictors of poor ...
Cogollo, E, Isenberg, DA, Silva, MA
core  

Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis [PDF]

open access: yes, 2012
BACKGROUND: Juvenile dermatomyositis (JDM) is a rare, often chronic, systemic autoimmune disease of childhood, characterized by inflammation of the microvasculature of the skeletal muscle and skin. Prominent clinical features include significant exercise
Anneli C Langbroek-Amersfoort   +4 more
core   +2 more sources

Frozen in Addiction: A New Wave of Drug‐Induced Movement Disorders?

open access: yes
Movement Disorders, EarlyView.
Christos Ganos   +12 more
wiley   +1 more source

Exome Sequencing Identifies a Novel Splicing Variant in COL9A3 Resulting in Multiple Epiphyseal Dysplasia: A Case Report

open access: yesMolecular Genetics &Genomic Medicine, Volume 13, Issue 11, November 2025.
A novel COL9A3 splice‐site variant was identified in a 14‐year‐old male misdiagnosed with juvenile idiopathic arthritis, confirming multiple epiphyseal dysplasia and emphasizing molecular testing as the key to unlocking accurate diagnosis in genetically heterogeneous skeletal disorders.
Bashayer Alnuaimi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy